Product logins

Find logins to all Clarivate products below.


Sunita Nair

Senior Director, Systematic Literature Reviews and Meta-analysis

Sunita Nair is a Practice Head at Clarivate, leading our Systematic Literature Reviews and Meta- analysis Centre of Excellence. Sunita is a business leader with 25 years experience and provides leadership to our highly skilled team of systematic reviewers and meta-analysis experts. She has supported several US FDA and HTA submissions. She has formerly worked in tertiary hospitals and multinational pharmaceutical companies (Sanofi, Novartis) in India. She has vast experience in establishing businesses, and managing teams providing services in HEOR, medical writing and clinical development. Her core areas of interest include cardiovascular research, HEOR, knowledge management, market access, market research, medical communications, molecular diagnostics, and scientific writing.​

Sunita is a regular speaker at scientific conferences, on the review panel of several journals, and a National Executive Committee member of the ISPOR India chapter.​

Sunita has a PhD in Applied Biology (Molecular Biology) and a master’s degree in Microbiology from the University of Mumbai, and a Post-Graduate Diploma in Global Health Policy from the London School of Hygiene and Tropical Medicine. She is also trained in Knowledge Management, carried out at the Indian Institute of Management.​


arrow_forward
Get in touch with Sunita

Latest news

News July 10, 2026
Clarivate to Report Second Quarter 2026 Results on July 29, 2026

London, U.K., July 10, 2026 – (PR Newswire) – Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced it will report its financial results for the second…

News July 9, 2026
Clarivate Releases G20 Research and Innovation Scorecard 2026

Tracking global research power, impact and collaboration as G20 priorities shift

News July 6, 2026
Clarivate Announces Sale of Life Sciences & Healthcare Segment for $600 Million

Transaction sharpens company’s focus on AI-driven transformative intelligence for its leading Academia & Government and Intellectual Property segments Enhances financial profile by improving revenue mix, expanding Adjusted EBITDA margin and…

Related resources

Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
Blog June 24, 2026
Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
ADC Biopharma Biotech Bispecific antibodies BsAb Clinical trials Development Oncology Pharma R&D Regulatory Research
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Blog June 22, 2026
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Biopharma Biotech Clinical trials CMC Development R&D Real-World Data Regulatory Research Safety
Three uncomfortable truths about cell and gene therapy in regulatory affairs Three uncomfortable truths about cell and gene therapy in regulatory affairs
Blog May 28, 2026
Three uncomfortable truths about cell and gene therapy in regulatory affairs
Consulting Resource Center Regulatory
How the Inflation Reduction Act could impact access to more convenient therapeutics How the Inflation Reduction Act could impact access to more convenient therapeutics
Blog February 17, 2026
How the Inflation Reduction Act could impact access to more convenient therapeutics
Biopharma Biotech Commercialization Consulting Resource Center FDA HMO Insurance Launch Managed care Market Access North America Payer Pharma pricing Route of administration U.S.